PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
3.54%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth less than half of TRVN's 1128.00%. David Dodd would verify if advantage is sustainable.
-10.44%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.44%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
721.68%
D&A change of 721.68% while TRVN maintains D&A. Bruce Berkowitz would investigate efficiency.
11.90%
EBITDA growth below 50% of TRVN's 27.53%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth below 50% of TRVN's 34.42%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Other expenses reduction while TRVN shows 287.50% growth. Joel Greenblatt would examine advantage.
10.28%
Pre-tax income growth below 50% of TRVN's 35.19%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth below 50% of TRVN's 35.19%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS growth below 50% of TRVN's 40.08%. Michael Burry would check for structural issues.
10.49%
Diluted EPS growth below 50% of TRVN's 40.08%. Michael Burry would check for structural issues.
2.21%
Share count reduction exceeding 1.5x TRVN's 7.99%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.